Şunu aradınız:: gpiib (Danca - İngilizce)

gpiib/ iiia
heparin bivalirudin +gpiib/ iiia

+gpiib/ iiia -
+gpiib/ iiia inhibitor

gpiib/iiia antagonister
gpiib/iiia antagonists

gpiib/iiia inhibitor (n=3008)%
inhibitor (n=3008)%

per-protokol heparin + gpiib/iiia -
results:30-day endpoints (intent-to-treat and per-protocol

behandling sammen med gpiib/ iiia inhibitorer
use with gpiib/ iiia inhibitors

samtidig brug af gpiib/iiia antagonister forøger blødningsrisikoen.
concomitant use of gpiib/iiia antagonists increases bleeding risk.

ufh/enox +gpiib/iiia -gpiib/iiia -bivalirudin
intent-to-treatufh/enox

angiox kan benyttes sammen med en gpiib/iiia-inhibitor.
angiox can be used in conjunction with a gp iib/iiia inhibitor.

gpiib/ iiia antagonister samtidig brug af gpiib/ iiia antagonister forøger blødningsrisikoen.
gpiib/ iiia antagonists concomitant use of gpiib/ iiia antagonists increases bleeding risk.

andre behandlinger såsom heparin og gpiib/iiia- inhibitorer blev administreret som skønnet af lægen.
other therapies, such as heparin and gpiib/iiia inhibitors, were administered at the discretion of the physician.

i cure blev 823 (6,6 %) patienter samtidig behandlet med gpiib/iiia-hæmmere.
in cure, 823 (6.6%) patients received concomitant gpiib/iiia receptor antagonist therapy.

data fra 366 patienter viser, at act ikke påvirkes af samtidig behandling med en gpiib/ iiia- inhibitor.
data from 366 patients indicates that the act is unaffected by concomitant treatment with a gpiib/ iiia inhibitor.

yderligere information om brug af bivalirudin med eller uden gpiib/ iiia- inhibitor kan findes i afsnit 5. 1.
refer to section 5.1 for further information regarding the use of bivalirudin with or without a gpiib/ iiia inhibitor.

i alt 356 patienter (7, 7%) som var randomiseret til arm c blev også behandlet med en gpiib/ iiia - inhibitor.
a total of 356 (7.7%) of patients randomised to arm c also received a gpiib/ iiia inhibitor.

24, 3%, 57, 5%) og gpiib/ iiia- hæmmere (rrr = 18, 2%, ci:
24.3%, 57.5%) and gpiib/ iiia inhibitors (rrr = 18.2%; ci:

patienter i arm a og b blev også randomiseret til behandling med gpiib/iiia-inhibitor enten på randomiseringstidspunktet (før angiografi) eller ved pci.
patients in arms a and b were also randomised to receive a gpiib/iiia inhibitor either upfront at the time of randomization (prior to angiography) or at the time of pci.

fordelene ved bivalirudin overfor ufh/ enoxaparin plus gpiib/ iiia- inhibitor i forhold til tilfælde af blødninger er kun overvåget i bivalirudin- monotarapiarmen.
the advantage of bivalirudin over ufh/ enoxaparin plus gpiib/ iiia inhibitor in terms of bleeding events was only observed in the bivalirudin monotherapy arm.

+gpiib/ iiia - +gpiib/ iiia - inhibitor inhibitor (n=4603) (n=4604)%%
or

i cure var anvendelse af clopidogrel forbundet med et aftagende behov for behandling med trombolytika (rrr = 43,3 %, ci: 24,3 %, 57,5 %) og gpiib/iiia-hæmmere (rrr = 18,2 %, ci: 6,5 %, 28,3 %).
the use of clopidogrel in cure was associated with a decrease in the need of thrombolytic therapy (rrr = 43.3%; ci: 24.3%, 57.5%) and gpiib/iiia inhibitors (rrr = 18.2%; ci: 6.5%, 28.3%).